Category: Federal Forum Posters
Purpose: During the course of Parkinson’s disease (PD), approximately 50% of patients will develop Parkinson’s disease psychosis (PDP). PDP consists of illusions, hallucinations, and delusions as a result of excess brain activity. Pimavanserin was developed to specifically target serotonin receptors while avoiding dopamine receptors. Post market safety is a concern, as increased reports of adverse effects are on the rise. Frequently reported adverse effects consist of hallucinations, confusion, and death. The primary and secondary objectives of this study are to evaluate the 12-month mortality rate pimavanserin and determine the appropriate use and safety of pimavanserin prescribing patterns at our institution.
Methods: This study will be a single site, retrospective chart review conducted at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC). All patients with current and past pimavanserin prescriptions will be identified using Veterans Health Information Systems and Technology Architecture (VistA) data. Patients 18 years and older with active pimavanserin prescription within December 1, 2016 through November 1, 2018 will be included in the study. Demographic data, pimavanserin indication and refill history, baseline EKG, concurrent psychotropic medications, prescriber type, and progress notes will be collected using the Computerized Patient Record System (CPRS). Information on previous hospitalizations related to mental health, documented adverse reactions, and causes of mortality will also be collected. Medication Possession Ratio will also be calculated for pimavanserin. Descriptive statistics will be used to calculate differences in baseline data, as appropriate.
Results: Not applicable
Conclusion: Not applicable
Kelsie Stark– Pharmacy Practice Resident, Michael E. DeBakey VA Medical Center, Houston, TX